Neurocrine Biosciences (NBIX) Revenue Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 2.94% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 77.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.66% |
| Dec 31, 2025 | 25.04% |
| Sep 30, 2025 | 27.02% |
| Jun 30, 2025 | 225.15% |
| Mar 31, 2025 | 22.62% |
| Dec 31, 2024 | 26.24% |
| Sep 30, 2024 | 28.09% |
| Jun 30, 2024 | 26.89% |
| Mar 31, 2024 | 29.62% |
| Dec 31, 2023 | 27.61% |
| Sep 30, 2023 | 24.50% |
| Jun 30, 2023 | 14.40% |
| Mar 31, 2023 | 21.03% |
| Dec 31, 2022 | 19.06% |
| Sep 30, 2022 | 20.43% |
| Jun 30, 2022 | -52.23% |
| Mar 31, 2022 | 30.92% |
| Dec 31, 2021 | 33.38% |
| Sep 30, 2021 | 24.94% |
| Jun 30, 2021 | 43.92% |